Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2013

Catalanotti Federica, Solit David B, Pulitzer Melissa P, Berger Michael F, Scott Sasinya N, Iyriboz Tunc, Lacouture Mario E, Panageas Katherine S, Wolchok Jedd D, Carvajal Richard D, Schwartz Gary K, Rosen Neal, Chapman Paul B

Abstract excerpt

PURPOSE: Test the hypothesis that in BRAF-mutated melanomas, clinical responses to selumetinib, a MEK inhibitor, will be restricted to tumors in which the PI3K/AKT pathway is not activated. EXPERIMENTAL DESIGN: We conducted a phase II trial in patients with melanoma whose tumors harbored a BRAF mutation. Patients were stratified by phosphorylated-AKT (pAKT) expression (high vs. low) and treated with selumetinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Drug Administration Schedule

Share to Exanthema

Share to Lymphopenia

Share to Mitogen-Activated Protein Kinase Kinases

Share to Proto-Oncogene Proteins c-akt

Source

Open in PubMed Open full text

Identifiers

PMID: 23444215
DOI: 10.1158/1078-0432.CCR-12-3476
PMCID: PMC3932005

Genes

BRAF
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.PMID 23444215Read ↗

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanomaSemantic proximity Read ↗

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.Semantic proximity Read ↗

CDK4/6 and SHP2 mediate BRAF/MEK inhibitor resistance in Class 2 and 3 BRAF mutant cancersSemantic proximity Read ↗

Dasatinib Resensitizes MAPK Inhibitor Efficacy in Standard-of-Care Relapsed MelanomasSemantic proximity Read ↗

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.Semantic proximity Read ↗

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF -Mutant MelanomaSemantic proximity Read ↗

MEK and the inhibitors: from bench to bedsideSemantic proximity Read ↗

Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.Semantic proximity Read ↗

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.